



Revance Therapeutics  
Investor Relations Department  
7555 Gateway Boulevard  
Newark, CA 94560  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: RVNC

Last Trade:	26.95
Trade Time:	4:00 PM ET Jun 26, 2017
Change:	0.55  (+2.083%)
Day Range	25.55 - 28.30
52-Week Range	12.35 - 26.78
Volume	376,614

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 15, 2017*

[Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery](#)

*Jun 5, 2017*

[Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial](#)

*Jun 1, 2017*

[Revance to Participate in Upcoming Investor Conferences](#)

*May 18, 2017*

[Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial](#)

*May 9, 2017*

[Revance Releases First Quarter 2017 Results](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Feb 28, 2017*

[Annual Report \(10-K\)](#)

*Mar 24, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 4, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 5, 2016*

[Quarterly Report \(10-Q\)](#)